The drugs changing how the world thinks about food may be changing something bigger. ABC News Nightline, with a follow-up on Good Morning America, went inside Caron Treatment Centers to report on early signs that GLP-1 medications like Ozempic and Mounjaro may curb more than food cravings.
Dr. Adam Scioli walks viewers through what clinicians were seeing, why the science points to the brain's reward system, and why GLP-1s belong alongside therapy and medical care rather than in place of them.
“A body of evidence that came about through both pre-clinical studies and clinical studies — one of which I was [at Caron] actually a part of with Penn State, first of its kind to explore the use of GLP-1 receptor agonist in residential substance use treatment settings for opioid use disorder. At the end of that study, when we saw 40% reduction in cravings, it was pretty compelling.”
Levelheaded is an independent company and is not affiliated with or endorsed by Caron Treatment Centers, Penn State, or the outlets referenced. Coverage is shared for informational purposes. GLP-1 medications are not FDA-approved for the uses discussed here, and the research described is early-stage.
